Compare OEC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OEC | AKBA |
|---|---|---|
| Founded | 1862 | 2007 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 380.4M |
| IPO Year | 2014 | 2014 |
| Metric | OEC | AKBA |
|---|---|---|
| Price | $6.03 | $1.33 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $6.44 | $5.75 |
| AVG Volume (30 Days) | 731.8K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,806,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.35 | $1.14 |
| 52 Week High | $13.02 | $4.08 |
| Indicator | OEC | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 45.88 |
| Support Level | $5.84 | $1.30 |
| Resistance Level | $6.58 | $1.55 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 86.00 | 6.25 |
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.